anti-interleukin-6 - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 hospitalized
	COVID 19 all comers
anti-interleukin-6
sarilumab
sarilumab high dose (400mg)	sarilumab phase 2 high dose
sarilumab low dose (200mg)	sarimulab phase 2 low dose
tocilizumab	BACC Bay Tocilizumab Trial TOCOVID

7 studies excluded by filtering options 2

5123	Gritti et al., 2020	2	30	0	excluded	not a RCT	risk of bias not avaialble
5366	Rimland, 2020	2	30	0	excluded	not a RCT	risk of bias not avaialble
5494	BREATH-19 Study, 0	2	30	0	excluded	not a RCT	risk of bias not avaialble
5523	Toniati, 2020	2	99	0	excluded	not a RCT	risk of bias not avaialble
5526	Price, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5632	Holt, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5672	Klopfenstein, 2020	2	13	4	excluded	not a RCT	high risk of bias